Scientists have discovered the key features of immune B cells which make them successful at targeting tumours - including when cancer has spread to a different part of the body.
Dr Ashwin Jainarayanan has been selected to become a 2024 Schmidt Science Fellow \u2013 an honour bestowed on only 32 exceptional early career researchers worldwide. The 2024 Fellows, nominated by 26 of the world\u2019s leading institutions across North America, Europe, and Asia, were chosen for their potential to drive sector-wide change by pursuing ambitious interdisciplinary science projects.
A first-of-its-kind study led by the University of Oxford has successfully investigated human immunity against COVID-19 in people who already have antibodies against it.
On Thursday 25th April 2024, the Oxford immunology community celebrated the kind donation of Sir Peter Medawar\u2019s Nobel Prize medal to the University.
Researchers from the Jenner Institute at NDM will present new exciting data on the R21/Matrix-M malaria vaccine during the 8th Pan-African Malaria Conference, in collaboration with the Rwandan Ministry of Health and the Rwanda Biomedical Centre.
A new programme of research led by Professor Claudia Monaco and funded by the British Heart Foundation aims to unpick the inflammatory processes behind cardiovascular disease so that immune-targeted therapies may be developed in future.
A new trial, SENTINEL, is set to investigate if skin patches can be used as an early warning system to identify if lung transplants are being rejected, so treatment can begin sooner, reducing the chance of longer lasting organ damage.
Serum Institute of India Pvt. Ltd (SIIPL), in collaboration with the University of Oxford, is developing a novel solution for Men-B disease, advancing global accessibility to life-saving vaccines.
University of Oxford researchers have for the first time established a controlled human infection model for tuberculosis (TB) that infects people via the lungs \u2013 the way TB enters the body.
The immune system in the intestine maintains a careful balance, tolerating our long-term resident (commensal) gut bacteria while defending against invading pathogens. Under certain circumstances, dysregulation of our intestinal immune response to commensal and pathogenic microbes can drive inflammatory disease.
New research by the CAMS Oxford Institute, the MRC Translational Immune Discovery Unit and the Kennedy Institute researchers describes a novel pairing of integrins which could improve T cell control of cancer.
The Thanks for the Memories public engagement programme \u2013 bringing together the worlds of immunology research and music composition for secondary school students in Manchester and Oxford \u2013 had a fantastic day with Manchester Co-op Academy students at the Science and Industry Museum in Manchester on Friday 8th March.
Researchers at the Nuffield Department of Medicine, the Francis Crick Institute and University College London have been granted \u00a31.7 million of funding from Cancer Research UK and the CRIS Cancer Foundation to develop a lung cancer vaccine. The group includes Professor Tim Elliott, Kidani Professor of Immuno-oncology at NDM.
A new understanding of the PD-1 axis (programmed death cell) could help shape ongoing efforts to improve treatments for cancer and autoimmune diseases.
CAMS-Oxford Institute Principal Investigator, Ricardo Fernandes, has been awarded a competitive grant from Cancer Research UK to study anti-tumour T cell responses.
New research published in Nature Communications suggests that the currently recommended five-day course of molnupiravir, an antiviral treatment, may not be long enough to treat COVID-19.
A new study led by the Big Data Institute at NDM has found persistent COVID-19 infections are surprisingly common, with around one to three in every 100 infections lasting a month or longer.
Recent findings by the Global Research on Antimicrobial Resistance Project at NDM's Centre for Tropical Medicine and Global Health revealed the resistance patterns for a priority pathogen--also known as typhoid fever--with high mortality and morbidity in resource-constrained settings.
![\"\"](\"https://www.immunology.ox.ac.uk/news/nature-nanotechnology-study-introduces-new-and-improved-version-of-all-in-one-coronavirus-vaccine/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n